Payers

HLTH The Future of Healthcare Event

April 16, 2018

HLTH is the leading event for innovation in healthcare. It’s an unprecedented, large-scale forum for individuals, companies and policymakers who are reshaping the healthcare industry to learn, collaborate and evolve. The event is unique in bringing together all key stakeholders, ranging from established payers, providers, employers, and pharma services to disruptive startups and prolific investors, […]

Clinigen receives PBS listing for TREXJECT® (methotrexate) in Australia for the treatment of rheumatoid arthritis and psoriasis

April 13, 2018

            Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, announces that TREXJECT® subcutaneous methotrexate pre-filled syringes, are now listed (from 1 April, 2018) on the Pharmaceutical Benefits Scheme (PBS) in Australia for the treatment of rheumatoid arthritis and psoriasis.   TREXJECT® syringes are Therapeutic Goods Administration (TGA) approved […]

Aetna Will Pass Along Discounts as Drug Price Scrutiny Increases

March 29, 2018

Aetna Inc. will pass on the discounts it negotiates on prescription drugs to about 3 million of its members, the latest move by a health insurer to address Americans’ complaints about the cost of medicine.   The discounts, which can amount to more than half a drug’s list price, will be passed on at the […]

Clinigen appointed by Jazz Pharmaceuticals to manage Managed Access Program for Vyxeos® (CPX-351) outside the United States

March 19, 2018

            Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has been appointed by Jazz Pharmaceuticals plc (NASDAQ: JAZZ, ‘Jazz’) to distribute Vyxeos® (daunorubicin and cytarabine) liposome for injection via a Managed Access Program (‘MAP’) outside the United States.   This MAP is for the treatment of adults aged 60-75 with newly-diagnosed, […]

Orbita rolls-out major enhancements to industry-leading voice and conversational AI platform to streamline development of healthcare applications

March 6, 2018

Contact: Beth Strohbusch, Orbita PR Director, beth@orbita.ai, +1 (414) 213-8818 Orbita Voice™ will showcase at HIMSS 2018 in Las Vegas, March 5-8, 2018. Boston, MA – March 5, 2018  – Orbita, Inc. today announced major enhancements to its Orbita Voice™ platform for creating powerful healthcare applications using voice assistive and conversational AI technology such as […]

Orbita rolls-out major enhancements to industry-leading voice and conversational AI platform to streamline development of healthcare applications

March 6, 2018

Contact: Beth Strohbusch, Orbita PR Director, beth@orbita.ai, +1 (414) 213-8818 Orbita Voice™ will showcase at HIMSS 2018 in Las Vegas, March 5-8, 2018. Boston, MA – March 5, 2018  – Orbita, Inc. today announced major enhancements to its Orbita Voice™ platform for creating powerful healthcare applications using voice assistive and conversational AI technology such as […]

Abarca, Amgen Enter Outcomes-Based Agreement For Repatha® (evolocumab) First-of-its-kind agreement between Amgen and a standalone PBM

February 23, 2018

MIAMI, Feb. 22, 2018 /PRNewswire/ — Abarca, a pharmacy benefit manager that is disrupting the industry with smarter technology and innovative strategies, today announced it has signed an outcomes-based contract with Amgen for the cholesterol-lowering drug, Repatha® (evolocumab). This agreement is the first of its kind involving Amgen’s Repatha and a standalone PBM.   “In […]

Idaho Blue Cross Jumps Into Controversial Market For Plans That Bypass ACA Rules

February 15, 2018

That didn’t take long.   It’s barely been two weeks since Idaho regulators said they would allow the sale of health insurance that does not meet all of the Affordable Care Act’s requirements — a controversial step some experts said would likely draw legal scrutiny and, potentially, federal fines for any insurer that jumped in. […]

AVEO Announces EUSA Pharma Granted Positive NICE Recommendation for FOTIVDA® (tivozanib) as First Line Treatment for Advanced Renal Cell Carcinoma

February 12, 2018

CAMBRIDGE, Mass. – February 12, 2018 – AVEO Oncology (NASDAQ:AVEO) today announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending FOTIVDA®(tivozanib) for the first line treatment of adult patients with advanced renal cell carcinoma (aRCC). In the European Union, Norway and Iceland, tivozanib […]

Two Labs Acquires MKO Global Partners

February 8, 2018

FOR IMMEDIATE RELEASE Media Contact: Alexis Marina alexis@gebencommunication.com 330-519-6892   Two Labs Acquires MKO Global Partners Company expands presence in the pharma consulting space with the addition of pricing and payer strategy services COLUMBUS, Ohio (February 8, 2018) – Two Labs, an industry-leading pharma and life science services company, today announced that it has acquired MKO […]

Acerus Pharma’s NATESTO® to Be Listed for Public Reimbursement in Quebec, Building on Strong 28% Increase in Natesto’s Canadian Prescriptions in Q4 2017

February 2, 2018

TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has received notice from Quebec’s National Institute for Excellence in Health and Social Services (INESSS) of a positive recommendation to the Health Minister for the inclusion of NATESTO® on the list of medications of the Régie de l’assurance maladie du Québec. This […]

Amazon, Berkshire Hathaway and J.P. Morgan Are Forming a Non-Profit Health Care Company

February 1, 2018

Amazon, Berkshire Hathaway, and J.P. Morgan Chase are forming a not-for-profit health care venture to lower health care costs for their U.S. employees, the companies announced Tuesday morning, sparking a slide in the shares of a host of health care-related companies. The initial focus of the independent company will be on technology that will provide […]

BIOGEN Optimistic for Rapid and Broad Patient Access Following Invitation to Submit SPINRAZA® (nusinersen)▼ to National Institute for Health and Care Excellence (NICE) for Single Technology Appraisal (STA)

January 22, 2018

MAIDENHEAD, England, January 22, 2018 /PRNewswire/ —   Managed Access Agreement to be developed in parallel to urgently provide effective new treatment to patients in England   The National Institute for Health and Care Excellence (NICE) has formally invited Biogen to submit SPINRAZA (nusinersen), the first and only disease-modifying treatment for 5q spinal muscular atrophy […]

RedHill Biopharma and Express Scripts Subsidiary Inside Rx Add EnteraGam® to Savings Program for Uninsured or Underinsured Patients

January 17, 2018

TEL-AVIV, Israel and RALEIGH, N.C., Jan. 17, 2018 (GLOBE NEWSWIRE) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases and cancer, today announced that EnteraGam® (serum-derived bovine immunoglobulin/protein isolate, SBI)1 was added to the […]

FEEDBACK